Rapport Therapeutics, Inc. (RAPP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 28.42M USD | Liabilities, Current |
| Cash and equivalents | 63.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 293.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.42M | $63.61M | (m) | $293.00K | (m) | (m) |
| 2026-03-31 | (m) | $17.90M | $78.06M | (m) | $58.00K | (m) | (m) |
| 2025-12-31 | (m) | $19.05M | $52.65M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $14.32M | $251.36M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $11.88M | $55.07M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.38M | $57.60M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $8.77M | $56.80M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $7.10M | $39.31M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $8.10M | $110.16M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $74.27M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $8.80M | $70.17M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $159.41M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $79.53M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |